JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Phase 2
Completed
Conditions
Pyoderma Gangrenosum
Interventions
Biological: Xilonix
First Posted Date
2013-10-18
Last Posted Date
2024-12-05
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
10
Registration Number
NCT01965613
Locations
🇺🇸

XBiotech Investigative Site, Tallahassee, Florida, United States

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

First Posted Date
2013-10-17
Last Posted Date
2014-12-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
40
Registration Number
NCT01964651

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

First Posted Date
2013-10-14
Last Posted Date
2019-05-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
19
Registration Number
NCT01962532

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

First Posted Date
2013-10-10
Last Posted Date
2019-01-04
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
219
Registration Number
NCT01959282

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

Phase 2
Terminated
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Ketamine
First Posted Date
2013-10-08
Last Posted Date
2017-01-27
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
13
Registration Number
NCT01957410

A Non-drug Study Profiling Cutaneous Lupus

First Posted Date
2013-08-15
Last Posted Date
2014-09-12
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
29
Registration Number
NCT01923415

An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

First Posted Date
2013-07-26
Last Posted Date
2016-03-02
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
257
Registration Number
NCT01909427

An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide

Completed
Conditions
Death, Sudden, Cardiac
Interventions
Drug: No intervention
First Posted Date
2013-07-25
Last Posted Date
2015-05-19
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
15000
Registration Number
NCT01907633

A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants

First Posted Date
2013-07-18
Last Posted Date
2016-11-01
Lead Sponsor
Janssen Research & Development, LLC
Registration Number
NCT01902550

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Phase 1
Completed
Conditions
Colitis, Ulcerative
Interventions
Drug: Golimumab
First Posted Date
2013-07-16
Last Posted Date
2023-05-11
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
35
Registration Number
NCT01900574
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy